Business
Nurix Therapeutics to Participate in Upcoming Investor Conference
BRISBANE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference in April. Needham Virtual Healthcare ConferenceArthur T. Sands, M.D., P
About this update from Nurix Therapeutics, Inc.
[{"type":"image","alt":"Nurix Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Nurix Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":124,"height":59,"url":"https://media.zenfs.com/en/globenewswire.com/d4426df492fc50ab857f27928363f9ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IT._.OAst_JFnczbzmuHbQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTEwMA--/https://media.zenfs.com/en/globenewswire.com/d4426df492fc50ab857f27928363f9ff","width":124,"height":59}},"lazy":false},{"type":"text","content":"BRISBANE, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference in April.","length":438,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Needham Virtual Healthcare ConferenceArthur T. Sands, M.D., Ph.D., president and chief executive officer of NurixMonday, April 13, 2026, at 1:30 – 2:10 p.m. ET","length":161,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":161,"olType":false},{"type":"text","content":"The fireside chat will be webcast live and may be viewed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event.","length":192,"tagName":"p"},{"type":"text","content":"About Nurix Therapeutics, Inc.Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline....